Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carvedilol in Pulmonary Arterial Hypertension
NCT02120339Phase 1Terminated
- Sponsor
- University of Minnesota
- Start
- May 2014
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of carvedilol in pulmonary arterial hypertension (PAH), sponsored by University of Minnesota. Primary endpoint: Right Ventricular Ejection Fraction at 6 months. Started May 2014; status: terminated.
02
Drugs
carvedilol
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT02120339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02120339.